BKD vs. GMTX, KNSA, VIR, OMCL, ANIP, AGTI, AKRO, GYRE, MORF, and ALHC
Should you be buying Brookdale Senior Living stock or one of its competitors? The main competitors of Brookdale Senior Living include Gemini Therapeutics (GMTX), Kiniksa Pharmaceuticals (KNSA), Vir Biotechnology (VIR), Omnicell (OMCL), ANI Pharmaceuticals (ANIP), Agiliti (AGTI), Akero Therapeutics (AKRO), Gyre Therapeutics (GYRE), Morphic (MORF), and Alignment Healthcare (ALHC). These companies are all part of the "medical" sector.
Brookdale Senior Living (NYSE:BKD) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
Brookdale Senior Living received 444 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 66.81% of users gave Brookdale Senior Living an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Brookdale Senior Living currently has a consensus price target of $7.50, indicating a potential upside of 8.54%. Given Brookdale Senior Living's higher probable upside, analysts clearly believe Brookdale Senior Living is more favorable than Gemini Therapeutics.
Brookdale Senior Living has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500.
Gemini Therapeutics has lower revenue, but higher earnings than Brookdale Senior Living. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Brookdale Senior Living, indicating that it is currently the more affordable of the two stocks.
Gemini Therapeutics has a net margin of 0.00% compared to Brookdale Senior Living's net margin of -5.71%. Gemini Therapeutics' return on equity of -38.78% beat Brookdale Senior Living's return on equity.
In the previous week, Brookdale Senior Living had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Brookdale Senior Living and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Brookdale Senior Living's score of -0.09 indicating that Gemini Therapeutics is being referred to more favorably in the news media.
75.4% of Gemini Therapeutics shares are owned by institutional investors. 1.5% of Brookdale Senior Living shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Brookdale Senior Living beats Gemini Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Brookdale Senior Living News Delivered to You Automatically
Sign up to receive the latest news and ratings for BKD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brookdale Senior Living Competitors List
Related Companies and Tools
